相似文献
1
Dyslipidemia in patients with chronic and end-stage kidney disease.
Cardiorenal Med. 2013 Oct;3(3):165-177. doi: 10.1159/000351985. Epub 2013 Jul 13.
2
Statins for treatment of dyslipidemia in chronic kidney disease.
Perit Dial Int. 2006 Sep-Oct;26(5):523-39.
3
The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Clin Nephrol. 2006 Nov;66(5):336-47. doi: 10.5414/cnp66336.
4
Dyslipidemia in patients with chronic kidney disease: etiology and management.
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.
5
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Cell Signal. 2019 Mar;55:53-64. doi: 10.1016/j.cellsig.2018.12.001. Epub 2018 Dec 12.
6
Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease.
Curr Opin Nephrol Hypertens. 2002 Mar;11(2):141-7. doi: 10.1097/00041552-200203000-00003.
7
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823.
8
Lipid abnormalities associated with end-stage renal disease.
Semin Dial. 2006 Jan-Feb;19(1):32-40. doi: 10.1111/j.1525-139X.2006.00117.x.
9
Dyslipidemia in patients with chronic kidney disease.
Rev Endocr Metab Disord. 2017 Mar;18(1):29-40. doi: 10.1007/s11154-016-9402-z.
10
Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
Pediatr Nephrol. 2015 Dec;30(12):2073-84. doi: 10.1007/s00467-015-3075-9. Epub 2015 Mar 24.
引用本文的文献
1
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.
Cardiovasc Drugs Ther. 2024 Nov 16. doi: 10.1007/s10557-024-07649-y.
2
Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?
J Res Med Sci. 2024 Jan 30;29:5. doi: 10.4103/jrms.jrms_136_21. eCollection 2024.
3
Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.
Redox Biol. 2023 Aug;64:102762. doi: 10.1016/j.redox.2023.102762. Epub 2023 Jun 2.
4
Lipid status association with 25-hydroxy vitamin D: Cross sectional study of end stage renal disease patients.
J Med Biochem. 2020 Sep 2;39(3):309-317. doi: 10.2478/jomb-2019-0032.
5
Dyslipidemia and Intraperitoneal Inflammation Axis in Peritoneal Dialysis Patients: A Cross-Sectional Pilot Study.
Kidney Dis (Basel). 2020 Jan;6(1):35-42. doi: 10.1159/000503632. Epub 2019 Nov 6.
6
Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.
Open Access Maced J Med Sci. 2019 Jul 25;7(15):2467-2473. doi: 10.3889/oamjms.2019.664. eCollection 2019 Aug 15.
7
The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
Int Urol Nephrol. 2019 Dec;51(12):2235-2242. doi: 10.1007/s11255-019-02319-7. Epub 2019 Oct 22.
8
Metabolic Syndrome and the Iodine-Dose/Creatinine Clearance Ratio as Determinants of Contrast-Induced Acute Kidney Injury.
Cardiorenal Med. 2018;8(3):217-227. doi: 10.1159/000488374. Epub 2018 Jun 15.
9
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.
Nat Rev Cardiol. 2017 Jul;14(7):387-400. doi: 10.1038/nrcardio.2017.34. Epub 2017 Mar 16.
10
Dyslipidemia in patients with chronic kidney disease: etiology and management.
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.
本文引用的文献
1
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.
2
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
3
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
4
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15.
5
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
6
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Am J Cardiol. 2011 Jun 15;107(12):1710-7. doi: 10.1016/j.amjcard.2011.02.336. Epub 2011 Apr 18.
7
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Clin J Am Soc Nephrol. 2011 Jun;6(6):1316-25. doi: 10.2215/CJN.09121010. Epub 2011 Apr 14.
8
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938.
9
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.
10
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
Zotero 插件